Dr. Avi Baskin is a urologic oncologist at the University of California, Irvine Medical Center, specializing in the surgical and multidisciplinary management of genitourinary cancers, including prostate, bladder, kidney, and testicular malignancies. He completed his medical degree at the David Geffen School of Medicine at UCLA, followed by urology residency at the University of California, San Francisco, and fellowship training in Urologic Oncology through the Society of Urologic Oncology at Vanderbilt University Medical Center. His clinical practice emphasizes precision cancer care, minimally invasive techniques, and integration of emerging technologies to improve patient outcomes.

In addition to his clinical work, Dr. Baskin leads research programs at the intersection of oncology, artificial intelligence, and health policy. His projects span clinical trial readability analysis, AI-powered patient engagement tools, transcriptomics-guided drug repurposing, and economic modeling of cancer care delivery. He has presented his research at national meetings and published in peer-reviewed journals, with the aim of translating data-driven insights into actionable improvements in patient care and healthcare systems. His work frequently bridges academic inquiry with real-world implementation, reflecting his commitment to innovation in both the clinic and the policy arena.

Dr. Baskin is an active peer reviewer for multiple scientific journals, including The Journal of Urology and The Journal of Sexual Medicine, and has served as an abstract reviewer for the American Urological Association. He has contributed to the National Comprehensive Cancer Network (NCCN) Patient Guidelines for Prostate Cancer, reinforcing his dedication to patient education and shared decision-making. Through his combined expertise in urologic oncology, technology integration, and healthcare reform, Dr. Baskin strives to advance a more personalized, efficient, and transparent future for cancer care.